B Freidlin

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Trend tests for case-control studies of genetic markers: power, sample size and robustness
    B Freidlin
    Biometric Research Branch, National Cancer Institute, Rockville, MD 20892, USA
    Hum Hered 53:146-52. 2002
  2. ncbi request reprint Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins
    M A Smith
    National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 17:569-77. 1999
  3. ncbi request reprint Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias
    B D Cheson
    The Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 17:2454-60. 1999
  4. ncbi request reprint Robust TDT-type candidate-gene association tests
    G Zheng
    National Heart Lung and Blood Institute, Bethesda, MD 20892, USA
    Ann Hum Genet 66:145-55. 2002
  5. ncbi request reprint Efficiency robust tests for survival or ordered categorical data
    B Freidlin
    Biometric Research Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Biometrics 55:883-6. 1999
  6. pmc Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases
    K G Becker
    Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 95:9979-84. 1998
  7. ncbi request reprint On power and efficiency robust linkage tests for affected sibs
    J L Gastwirth
    Division of Cancer Genetics and Epidemiology, National Cancer Institute, Bethesda, MD 20892, USA
    Ann Hum Genet 64:443-53. 2000
  8. ncbi request reprint Trends in reported incidence of primary malignant brain tumors in children in the United States
    M A Smith
    Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA
    J Natl Cancer Inst 90:1269-77. 1998
  9. doi request reprint Assessing causal relationships between treatments and clinical outcomes: always read the fine print
    B Freidlin
    Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 6130 Executive Plaza, Bethesda, MD 20892, USA
    Bone Marrow Transplant 47:626-32. 2012
  10. ncbi request reprint Unconditional versions of several tests commonly used in the analysis of contingency tables
    B Freidlin
    Biometric Research Branch, National Cancer Institute, Bethesda, Maryland 20892 7434, USA
    Biometrics 55:264-7. 1999

Collaborators

Detail Information

Publications11

  1. ncbi request reprint Trend tests for case-control studies of genetic markers: power, sample size and robustness
    B Freidlin
    Biometric Research Branch, National Cancer Institute, Rockville, MD 20892, USA
    Hum Hered 53:146-52. 2002
    ..Simulation results of the robustness of these two tests indicate that the more computationally involved MAX test is preferable...
  2. ncbi request reprint Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins
    M A Smith
    National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 17:569-77. 1999
    ..The Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) has developed a monitoring plan to obtain reliable estimates of the risk of secondary leukemia after epipodophyllotoxin treatment...
  3. ncbi request reprint Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias
    B D Cheson
    The Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 17:2454-60. 1999
    ..The purpose of the present study was to assess the frequency of second tumors in patients with CLL who are treated with fludarabine and in patients with HCL who are treated with DCF and CdA...
  4. ncbi request reprint Robust TDT-type candidate-gene association tests
    G Zheng
    National Heart Lung and Blood Institute, Bethesda, MD 20892, USA
    Ann Hum Genet 66:145-55. 2002
    ..g. dominant through additive) a simple linear combination also performs well. In general, the MAX has better power properties than the TDT for the study of candidate genes when the mode of inheritance is unknown...
  5. ncbi request reprint Efficiency robust tests for survival or ordered categorical data
    B Freidlin
    Biometric Research Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Biometrics 55:883-6. 1999
    ..The second procedure, called the MX, uses the maximum of the optimal statistics. Both approaches yield efficiency robust procedures for survival analysis and ordinal categorical data. Guidelines for choosing between them are provided...
  6. pmc Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases
    K G Becker
    Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 95:9979-84. 1998
    ..This nonrandom clustering supports a hypothesis that, in some cases, clinically distinct autoimmune diseases may be controlled by a common set of susceptibility genes...
  7. ncbi request reprint On power and efficiency robust linkage tests for affected sibs
    J L Gastwirth
    Division of Cancer Genetics and Epidemiology, National Cancer Institute, Bethesda, MD 20892, USA
    Ann Hum Genet 64:443-53. 2000
    ..When the minimal correlation is less than 0.5, an alternate robust procedure is proposed. The methods apply to combining data from sibships of different sizes...
  8. ncbi request reprint Trends in reported incidence of primary malignant brain tumors in children in the United States
    M A Smith
    Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA
    J Natl Cancer Inst 90:1269-77. 1998
    ....
  9. doi request reprint Assessing causal relationships between treatments and clinical outcomes: always read the fine print
    B Freidlin
    Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 6130 Executive Plaza, Bethesda, MD 20892, USA
    Bone Marrow Transplant 47:626-32. 2012
    ..At the same time, we illustrate how careful application of special statistical methods for assessment of treatment-outcome causation can be instrumental in complementing existing randomized evidence and guiding design of future research...
  10. ncbi request reprint Unconditional versions of several tests commonly used in the analysis of contingency tables
    B Freidlin
    Biometric Research Branch, National Cancer Institute, Bethesda, Maryland 20892 7434, USA
    Biometrics 55:264-7. 1999
    ..The unconditional procedures are compared to the conditional ones by reanalyzing some published biomedical data...
  11. ncbi request reprint Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results
    O S Breathnach
    Lowe Center for Thoracic Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 19:1734-42. 2001
    ..Techniques for improved use of patient resources and appropriate trial design for phase III randomized therapeutic trials with patients with advanced NSCLC need to be developed...